Back to top
more

Aytu BioPharma, Inc. (AYTU)

(Delayed Data from NSDQ)

$2.31 USD

2.31
53,613

+0.21 (9.74%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.24 -0.07 (-3.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -153.85% and +9.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for Oct. 13th

by Zacks Equity Research

AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.

Zacks Equity Research

Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Agilent (A) delivered earnings and revenue surprises of +0.74% and +4.60%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 244.12% and 28.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Aytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Aytu BioPharma Inc. (AYTU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Zacks Equity Research

Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.